{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:59:03Z","timestamp":1784908743618,"version":"3.55.0"},"reference-count":22,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To evaluate whether treatment with insulin in recently diagnosed type 2 diabetes is advantageous compared with glibenclamide treatment.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014\u03b2-Cell function, glycemic control, and quality of life were monitored over 2 years in 39 patients with islet cell antibody-negative type 2 diabetes diagnosed 0\u20132 years before inclusion in a Swedish multicenter randomized clinical trial. Patients were randomized to either two daily injections of premixed 30% soluble and 70% NPH insulin or glibenclamide (3.5\u201310.5 mg daily). C-peptide-glucagon tests were performed yearly in duplicate after 2\u20133 days of temporary withdrawal of treatment.<\/jats:p>\n               <jats:p>RESULTS\u2014After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.14 \u00b1 0.08 nmol\/l, whereas it was decreased by 0.12 \u00b1 0.08 nmol\/l in the glibenclamide group, P &amp;lt; 0.02 for difference between groups. After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamide-treated group (P = 0.02). HbA1c levels decreased significantly during the first year in both groups; however, at the end of the second year, HbA1c had deteriorated in the glibenclamide group (P &amp;lt; 0.01), but not in the insulin-treated group. The difference in evolution of HbA1c during the second year was significant between groups, P &amp;lt; 0.02. A questionnaire indicated no difference in well-being related to treatment.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Early insulin versus glibenclamide treatment in type 2 diabetes temporarily prolongs endogenous insulin secretion and promotes better metabolic control.<\/jats:p>","DOI":"10.2337\/diacare.26.8.2231","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"2231-2237","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":131,"title":["Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patients"],"prefix":"10.2337","volume":"26","author":[{"given":"Michael","family":"Alvarsson","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go\u0308ran","family":"Sundkvist","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Malmo\u0308 University Hospital, Malmo\u0308, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibe","family":"Lager","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kristianstad Hospital, Kristianstad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Henricsson","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Helsingborg Hospital, Helsingborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Berntorp","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Malmo\u0308 University Hospital, Malmo\u0308, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fernqvist-Forbes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Visby Hospital, Visby, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Steen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ma\u0308larsjukhuset, Eskilstuna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Westermark","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Faculty of Health Sciences, Linko\u0308ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Westermark","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Faculty of Health Sciences, Linko\u0308ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u0308rn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Blekingesjukhuset, Karlskrona, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdemar","family":"Grill","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031215171355600_R1","doi-asserted-by":"crossref","unstructured":"UK Prospective Study Group: U.K. Prospective Diabetes Study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes\u200844: 1249\u20131258, 1995","DOI":"10.2337\/diab.44.11.1249"},{"key":"2022031215171355600_R2","doi-asserted-by":"crossref","unstructured":"Clauson P, Linnarsson R, Gottsater A, Sundkvist G, Grill V: Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med\u200811:794\u2013801, 1994","DOI":"10.1111\/j.1464-5491.1994.tb00355.x"},{"key":"2022031215171355600_R3","doi-asserted-by":"crossref","unstructured":"Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark A, Ostman J, Arnqvist HJ, Blohme G, Bolinder J, Eriksson JW, Lithner F, Schersten B, Wibell L: Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment: a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care\u200822:409\u2013412, 1999","DOI":"10.2337\/diacare.22.3.409"},{"key":"2022031215171355600_R4","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA, New England Medical Center, The Health Institute, 1993"},{"key":"2022031215171355600_R5","doi-asserted-by":"crossref","unstructured":"Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V: Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem\u200832:1867\u20131872, 1986","DOI":"10.1093\/clinchem\/32.10.1867"},{"key":"2022031215171355600_R6","doi-asserted-by":"crossref","unstructured":"Henricsson M, Berntorp K, Berntorp E, Fernlund P, Sundkvist G: Progression of retinopathy after improved metabolic control in type 2 diabetic patients: relation to IGF-1 and hemostatic variables. Diabetes Care\u200822:1944\u20131949, 1999","DOI":"10.2337\/diacare.22.12.1944"},{"key":"2022031215171355600_R7","doi-asserted-by":"crossref","unstructured":"Landin-Olsson M, Sundkvist G, Lernmark A\u030a Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia\u200830:327\u2013332, 1987","DOI":"10.1007\/BF00299026"},{"key":"2022031215171355600_R8","doi-asserted-by":"crossref","unstructured":"Borg H, Fernlund P, Sundkvist G: Measurement of antibodies against glutamic acid decarboxylase (GADA): two new 1125-assays compared with S35-GAD 65-ligand binding assay. Clin Chem\u200843:779\u2013785, 1997","DOI":"10.1093\/clinchem\/43.5.779"},{"key":"2022031215171355600_R9","doi-asserted-by":"crossref","unstructured":"Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, Sundkvist G: Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care\u200819:142\u2013145, 1996","DOI":"10.2337\/diacare.19.2.142"},{"key":"2022031215171355600_R10","doi-asserted-by":"crossref","unstructured":"Christmanson L, Betsholtz C, Leckstrom A, Engstrom U, Cortie C, Johnson KH, Adrian TE, Westermark P: Islet amyloid polypeptide in the rabbit and European hare: studies on its relationship to amyloidogenesis. Diabetologia\u200836:183\u2013188, 1993","DOI":"10.1007\/BF00399947"},{"key":"2022031215171355600_R11","doi-asserted-by":"crossref","unstructured":"Leckstrom A, Ostenson CG, Efendic S, Arnelo U, Permert J, Lundquist I, Westermark P: Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas\u200813:259\u2013267, 1996","DOI":"10.1097\/00006676-199610000-00008"},{"key":"2022031215171355600_R12","doi-asserted-by":"crossref","unstructured":"Faber OK, Binder C: C-peptide response to glucagon: a test for the residual beta-cell function in diabetes mellitus. Diabetes\u200826:605\u2013610, 1977","DOI":"10.2337\/diabetes.26.7.605"},{"key":"2022031215171355600_R13","doi-asserted-by":"crossref","unstructured":"Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kuhl C: Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand\u2008222:71\u201374, 1987","DOI":"10.1111\/j.0954-6820.1987.tb09931.x"},{"key":"2022031215171355600_R14","doi-asserted-by":"crossref","unstructured":"Gottsater A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark A, Sundkvist G: Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation: a comparison between insulin and C-peptide to measure insulin secretion. Scand J Clin Lab Invest\u200852:631\u2013639, 1992","DOI":"10.3109\/00365519209115506"},{"key":"2022031215171355600_R15","doi-asserted-by":"crossref","unstructured":"Gjessing HJ, Reinhold B, Pedersen O: The effect of chronic hyperglycaemia on the islet B-cell responsiveness in newly diagnosed type 2 diabetes. Diabet Med\u20089:601\u2013604, 1992","DOI":"10.1111\/j.1464-5491.1992.tb01853.x"},{"key":"2022031215171355600_R16","doi-asserted-by":"crossref","unstructured":"Berger B, Stenstrom G, Sundkvist G: Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest\u200860:687\u2013693, 2000","DOI":"10.1080\/00365510050216411"},{"key":"2022031215171355600_R17","doi-asserted-by":"crossref","unstructured":"Arnold-Larsen S, Madsbad S, Kuhl C: Reproducibility of the glucagon test. Diabet Med\u20084:299\u2013303, 1987","DOI":"10.1111\/j.1464-5491.1987.tb00884.x"},{"key":"2022031215171355600_R18","doi-asserted-by":"crossref","unstructured":"Groop L, Barzilai N, Ratheiser K, Luzi L, Wallin-Boll E, Melander A, De Fronzo R: Dose-dependent effects of glyburide on insulin secretion and glucose: uptake in humans. Diabetes Care\u200814:724\u2013727, 1991","DOI":"10.2337\/diacare.14.8.724"},{"key":"2022031215171355600_R19","doi-asserted-by":"crossref","unstructured":"Jo\u0308nsson A, Hallengren B, Rydberg T, Melander A: Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes: Diabetes Obes Metab\u20083:403\u2013409, 2001","DOI":"10.1046\/j.1463-1326.2001.00152.x"},{"key":"2022031215171355600_R20","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031215171355600_R21","doi-asserted-by":"crossref","unstructured":"Stout RW: Insulin and atheroma: 20-yr perspective (Review Article). Diabetes Care\u200813:631\u2013654, 1990","DOI":"10.2337\/diacare.13.6.631"},{"key":"2022031215171355600_R22","doi-asserted-by":"crossref","unstructured":"Birkeland KI, Rishaug U, Hanssen KF, Vaaler S: NIDDM: a rapid progressive disease: results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia\u200839:1629\u20131633, 1996","DOI":"10.1007\/s001250050626"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/8\/2231\/660955\/dc0803002231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/8\/2231\/660955\/dc0803002231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T15:17:28Z","timestamp":1647098248000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/26\/8\/2231\/22886\/Beneficial-Effects-of-Insulin-Versus-Sulphonylurea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.26.8.2231","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}